Balcom Alexandra 4
4 · Nuvalent, Inc. · Filed Apr 3, 2026
Research Summary
AI-generated summary of this filing
Nuvalent (NUVL) CFO Alexandra Balcom Sells Shares, Exercises Options
What Happened
Alexandra Balcom, Chief Financial Officer of Nuvalent, exercised 11,430 option-derived shares and immediately sold those 11,430 shares in three open-market transactions on April 1, 2026. She acquired the shares via exercise at $1.08 per share (cost $12,344) and sold them in blocks for total gross proceeds of $1,202,526 — net of the exercise cost, roughly $1.19M in proceeds. These sales are reported as routine dispositions rather than new purchases.
Key Details
- Transaction date: April 1, 2026; Form 4 filed April 3, 2026 (timely filing).
- Exercise (M): 11,430 shares acquired at $1.08 each (reported cost $12,344). Footnote F5: underlying option fully vested.
- Sales (S): 3,544 shares at weighted avg $104.39 (prices ranged $103.81–$104.79) = $369,958 (F2); 5,417 shares at weighted avg $105.30 (range $104.84–$105.83) = $570,410 (F3); 2,469 shares at weighted avg $106.18 (range $105.85–$106.69) = $262,158 (F4). Total proceeds = $1,202,526.
- Reported plan: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted Dec 23, 2025 (F1).
- Shares owned after transaction: Not specified in the excerpted filing provided.
- Filing timeliness: Not marked late; filing date is Apr 3 for Apr 1 trades.
Context
This is an exercise-and-sale (commonly a cashless exercise) where options were converted into shares and those shares were sold the same day — a routine way for insiders to monetize vested options. The presence of a 10b5-1 plan indicates the sales were pre-scheduled; such sales are typically considered routine and do not, by themselves, indicate insider sentiment about the company’s prospects.
Insider Transaction Report
- Exercise/Conversion
Class A Common Stock
[F1]2026-04-01$1.08/sh+11,430$12,344→ 96,963 total - Sale
Class A Common Stock
[F1][F2]2026-04-01$104.39/sh−3,544$369,958→ 93,419 total - Sale
Class A Common Stock
[F1][F3]2026-04-01$105.30/sh−5,417$570,410→ 88,002 total - Sale
Class A Common Stock
[F1][F4]2026-04-01$106.18/sh−2,469$262,158→ 85,533 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]2026-04-01−11,430→ 138,796 totalExercise: $1.08Exp: 2031-02-16→ Class A Common Stock (11,430 underlying)
Footnotes (5)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2025.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.81 to $104.79, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) of this Form 4.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.84 to $105.83, inclusive.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.85 to $106.69, inclusive.
- [F5]The shares underlying this option are fully vested.